Product Type: Inhibitor
CAS No.: 256373-96-3
MolecularFormula: C20H23N2O5S ∙ Na
Molecular Weight: 426,5
Source: Synthetic
Purity: >98% (HPLC); NMR (Conforms)
Solubility: May be dissolved in water (30 mg/ml): or DMSO (40 mg/ml)
Appearance: White powder
PubChem CID: 1234617
Scientific Background: MCC950 was originally found to act as a cytokine release inhibitory drug (CRID), arresting activated monocytes and preventing activation of caspase-1(1). Discovered to be a novel inhibitor of the NLRP3 and AIM2 inflammasomes(2). Blocks canonical and noncanonical NLRP3 activation at nanomolar concentrations3. Inhibits interleukin 1β (IL-1β) secretion in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (an MS disease model)(3). Disrupts the interaction between AIM2 and ASC in a reconstituted cell-free inflammasome(4). A valuable new tool for exploring the pathophysiology of NLRP3. It may contribute to additional alpha synuclein aggregation and cell loss in PD (5).
References: 1. Laliberte R.E. et al. (2003) J. Biol. Chem. 278(19):16567-78.2. Coll R.C., et al. (2011) PLoS One. 6(12):e29539.3. Coll R.C., et al. (2015) Nat. Med. 21(3):248-255.4. Kaneko N., et al. (2015) J. Immunol. Methods. 426:76-81. 5. Nguyen L., et al. (2022) J Parkinsons Dis. 12(7): 2117-2133.
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
Deutsch
English
